



Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

April 19, 2022

IRVINE, Calif.--(BUSINESS WIRE)--Apr. 19, 2022-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the Axonics F15 across the United States. The newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system received FDA [approval](#) in March.

"The Axonics recharge-free system is a welcome advancement for patients suffering from bladder and bowel dysfunction," said Taylor Moore, M.D., board-certified urologist at Arkansas Urology. "My initial implants of the new device have gone well, with low amplitudes achieved at the time of implant suggesting longevity in the body of around 20 years. Clinical outcomes with the Axonics rechargeable SNM system have exceeded our expectations and we anticipate similar results with the Axonics F15. We are pleased to now offer patients a non-rechargeable option that provides significant longevity in the body, constant current stimulation, and a remote control that is recharge-free and easy for patients to use."

About Axonics F15

- **INS type:** primary cell battery
- **INS longevity:** functional life has been validated for over 15 years at typical stimulation parameters and over 20 years at lower energy settings
- **INS volume:** 10 cubic centimeters (20% smaller than the market's other non-rechargeable SNM device)
- **Stimulation:** constant current automatically adjusts stimulation output
- **Tined lead:** universal tined lead compatible with both recharge-free and rechargeable Axonics systems
- **MRI compatibility:** full body with 1.5T and 3.0T whole-body scanners
- **Patient remote control:** intuitive, recharge-free key fob featuring *SmartMRI™* technology
- **Programming:** proprietary algorithm recommends optimal stimulation parameters based on intraoperative responses

Raymond W. Cohen, CEO of Axonics, said, "Physician response to the Axonics F15 has been overwhelmingly positive. Our sales team is now armed with a complete portfolio of SNM products that, along with our national DTC [campaign](#), will contribute to Axonics achieving its mission of treating more adults suffering from incontinence. We remain confident that our commitment to innovation, quality, and providing physicians and patients strong support will continue to drive SNM market expansion and advance Axonics on its path to market leadership."

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Axonics' sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company's best-in-class urethral bulking hydrogel, Bulkamid® , provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220419005467/en/): <https://www.businesswire.com/news/home/20220419005467/en/>

Neil Bhalodkar
Investor Relations
949-336-5293
ir@axonics.com

Source: Axonics, Inc.